Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Içli, F.
Right arrow Articles by Erekul, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Içli, F.
Right arrow Articles by Erekul, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:1011-1013, 2001
© 2001 European Society for Medical Oncology

research-article

A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) ± two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer*

F. Içli1, H. Akbulut1, D. Dincol1, H. Onur1, A. Demirkazik1, R. çam2, F. çay1, S. Demirci2, A. Üner3 and S. Erekul4

1Department of Medical Oncology, Ankara University Sihhiye-Ankara, Turkey
2Surgical Oncology, Ibni Sina Hospital, Faculty of Medicine Ankara University Sihhiye-Ankara Turkey
3Department of Medical Oncology, Faculty of Medicine, Gazi University, Besevler-Ankara Sihhiye-ankara, Turkey
4Department of Pathology Faculty of Medicine, Ankara University Sihhiye-Ankara, Turkey

Background: Four cycles of AC have been accepted as the standard chemotherapy in breast cancer. In the present randomized study we aimed to assess the efficacy of adjuvant etoposide + cisplatin (EP) combination following four cycles of standard adriamycin + cyclophosphamide (AC) in prernenopausal patients with operable breast cancer and axillary lymph node metastasis.

Patients and methods: Premenopausal patients with positive axillary lymph nodes following curative modified radical mastectomy were randomized to either four cycles of AC (82 patients) or four cycles of AC + two cycles of EP (83 patients).

Results. Median follow-up is 72 months. All randomized and eligible patients are included in the analysis (AC: 80 patients, AC + EP: 78 patients). The five-year disease-free survival (DFS) for the AC + EP group was significantly better when compared to AC group (45.5% vs. 30.4% P= 0.048). Again, the five-year overall survival (OS) of the whole group was in favor of AC + EP arm, though without statistical significance (68.6% vs. 59.l% P= 0.247).

Conclusion: Two cycles of EP following four cycles of AC decreased the relapse rate in operable breast cancer patients.

adjuvant chemotherapy, adriamycin, breast cancer, cisplatin, cyclophosphosphamide, etoposide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.